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Objectives and Background: Serum biomarkers have been proposed to reflect
fibrosis of several human tissues, but their specific role in the detection of myocardial
fibrosis has not been well-established. We studied the association between N-terminal
propeptide of type I and III procollagen (PINP, PIIINP, respectively), galectin-3 (gal-3),
soluble ST2 (ST2), and myocardial fibrosis measured by late gadolinium enhanced
cardiac magnetic resonance imaging (LGE CMR) and their relation to left ventricular
diastolic filling properties measured by tissue Doppler echocardiography (E/e’) in patients
with stable coronary artery disease (CAD).
Methods and Results: We determined the PINP, PIIINP, gal-3, and ST2 serum levels
and performed LGE CMR and echocardiography on 63 patients with stable CAD without
a history of prior myocardial infarction. Myocardial late gadolinium enhancement T1
relaxation time was defined as a specific marker of myocardial fibrosis. ST2, PINP, and
PIIINP did not have a significant correlation with the post-LGE T1 relaxation time tertiles
(NS for all), but the lowest post-LGE T1 relaxation time tertile had significantly higher
gal-3 values than the other two tertiles (p = 0.002 and 0.002) and higher E/é-values
(p = 0.009) compared to the highest T1 relaxation time tertile. ST2 (p = 0.025 and
0.029), gal-3 (p = 0.003 and < 0.001) and PIIINP (p = 0.001 and 0.007) levels were
also significantly higher in the highest E/é tertile, compared to the other two tertiles.
Conclusions: Elevated serum levels of gal-3 reflect the degree of myocardial fibrosis
assessed by LGE CMR. Gal-3, ST2, and PIIINP are also elevated in patients with impaired
LV diastolic function, suggesting that these biomarkers are useful surrogates of structural
and functional abnormality of the myocardium.
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Introduction
Impaired left ventricular (LV) diastolic filling in subjects with
preserved LV function has been associated with worse outcome
among coronary artery disease (CAD) patients and patients
with heart failure with preserved LV function (Rusinaru et al.,
2014). The etiological background for impaired LV diastolic
filling properties is not well-known, but one possible underlying
mechanism could be the accumulation of diffuse fibrosis in
the myocardium. Diffuse interstitial fibrosis can be assessed
with cardiovascular magnetic resonance imaging (CMR) by
using late gadolinium enhancement (LGE). Relaxation time T1
mapping has been shown to correlate with interstitial fibrosis
measured from endomyocardial biopsies or with invasively
measured left ventricular stiffness (Iles et al., 2008; Miller et al.,
2013; Ellims et al., 2014). Many biomarkers of fibrosis have
also been proposed to reflect myocardial fibrosis. Biomarkers
related to fibrosis, such as N-terminal propeptide of type I
and III procollagens (PINP and PIIINP, respectively), galectin-
3 (gal-3), and soluble ST2 protein (ST2) have been associated
with poor outcome among heart failure patients (Cicoira
et al., 2004; Pascual-Figal et al., 2009; Velagaleti et al., 2010;
De Boer et al., 2011; Bayes-Genis et al., 2012; Lok et al.,
2013). Although these biomarkers may have predictive value,
their ability to detect myocardial interstitial fibrosis is not
well-established.
The aim of this study was to determine the association of
fibrosis biomarkers and myocardial interstitial fibrosis measured
by LGE CMR and their relation to left ventricular diastolic filling
measured by tissue Doppler echocardiography in patients with
stable coronary artery disease (CAD).
Materials and Methods
Patient Population
Sixty-three consecutive patients with angiographically
documented stable CAD were prospectively recruited from
the ARTEMIS-Oulu database (Cardiovascular Complications
in Type II Diabetes Study; registered at ClinicalTrials.gov,
Record 1539/31/06, Identifier NCT01426685). The exclusion
criteria included rhythm other than sinus rhythm, reduced
left ventricular ejection fraction, greater than mild valvular
disease or previous valve surgery, clinical history of myocardial
infarction (Q-waves in ECG, myocardial scar, or segmental wall
motion abnormalities seen in echocardiography), permanent
pacemaker, significant renal disease, and claustrophobia.
The study was approved by the local institutional ethics
committee. Written informed consent was obtained from all the
patients.
Abbreviations: LV, left ventricle; EF, ejection fraction; CAD, coronary artery
disease; CMR, cardiovascular magnetic resonance; LGE, late gadolinium
enhancement; PINP, N-terminal propeptide of type I procollagen; PIIINP, N-
terminal propeptide of type III procollagen; Gal-3, galectin-3; ST2, soluble ST2
protein; ELISA, enzyme-linked immunosorbent assay; TR, time to repetition; TE,
time to echo; TI, inversion time; BMI, body mass index; GHbA1c, Glycosylated
Hemoglobin, Type A1C; BNP, brain natriuretic peptide; hs-CRP, high sensitive
C-reactive protein.
Biomarkers
The concentrations of gal-3 and ST2 were determined from
serum samples. Serum was prepared by allowing the blood
to clot for 30min followed by centrifugation at 2000 ×g for
10min. The serum was stored at -20◦C until analyzed. ST2 levels
were analyzed using a sandwich, enzyme-linked immunosorbent
assay (ELISA) (Human ST2/IL-1 R4 Quantikine ELISA, R&D
Systems Inc., Minneapolis, MN) with a sensitivity of 5.1 pg/mL.
Gal-3 levels in serum were determined by an enzyme-linked
immunosorbent assay (ELISA) from BG Medicine (Waltham,
MA, USA). The limit of detection (LoD) for the assay was
1.13 ng/mL (Christenson et al., 2010).
Serum Intact PINP concentrations (Koivula et al., 2010) were
analyzed with the automated iSYS instrument (IDS, Newcastle,
U.K) using 20µL samples and serum PIIINP (Risteli et al.,
1988) concentrations with specific radioimmunoassays (Orion
Diagnostica, Espoo, Finland) using 200µL or 100µL samples,
respectively.
Echocardiography
A thorough transthoracic echocardiographic evaluation was
made utilizing the same General Electric Vivid seven for all
patients. Parasternal long axis view and M-mode were used to
obtain left ventricular (LV) diameters and wall thickness. LV
mass was derived from the ASE equation. LV ejection fraction
was measured from the apical view by the biplane method from
the 2- and 4-chamber views. Left ventricular diastolic filling was
assessed by end-expiration ratio of peak early diastolic mitral
velocity to tissue Doppler-derived peak early diastolic mitral
annular velocity measured in the septal mitral annulus (E/é).
Late Gadolinium Enhancement CMR
CMR with the same 1.5T scanner (GE Optima MR450w, GE
Healthcare, Milwaukee, WI) and 32-channel cardiac coil was
performed on all the patients. Mid-ventricular short axis images
were obtained. T1 was measured i.e., T1 mapping was performed
with a ECG-triggered Look-Locker sequence (TR 4440 s, TE
2.016ms, 30 TI’s between 95 and 1279ms, in-plane resolution
1.48mm, slice thickness 8mm). The images were acquired
during breath holds. MRI images were analyzed off-line using
an in-house MATLAB application (Matlab, MathWorks Inc,
Natick, MA). Regions of interest were segmented manually.
The segments with visible LGE i.e., replacement fibrosis were
excluded from the analysis. The possible position differences
between images with different TI’s were taken into account by
segmenting each image separately and calculating ROI-wise T1
using the mean intensities of each image. T1 relaxation time was
measured 10–15min after contrast agent injection (0.4mL/kg but
not more than 30mL of Dotarem (500mM, Guerbet AG, Zürich,
Switzerland).
Statistical Analysis
All continuous data are presented as mean± standard deviation.
IBM R© SPSS R© Statistics v. 21 (IBM Corp., Armonk, NY) was
used to analyze all statistics. Because of the skewed distribution
of the variables, no correlation co-efficient were analyzed. For
the same reason and due to the small study population we
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tested differences between tertiles divided according to LGE T1
relaxation time and E/é. Oneway analysis of variance was used
followed by post hoc Bonferroni test in comparisons between the
tertiles. All results with p < 0.05 were considered statistically
significant.
Results
The mean T1 relaxation time was 365 (±43.9) ms, the mean
value of E/é 9.77 (±4.92) and the concentration of ST2 was 20.37
(±6.62) ng/mL, of gal-3 12.13 (±4.93) ng/mL, of PINP 36.27
(±16.29) ng/mL, and that of PIIINP 3.81µg/L (±1.13).
Age, gender, BMI, diabetes, history of smoking, medication,
blood pressure, left ventricular ejection fraction, LV mass, and
LV mass index, Syntax score, renal function, HbA1c levels,
serum cholesterol levels, high sensitive CRP, and BNP levels did
not differ significantly between the T1 relaxation time tertiles
(Table 1).
Subjects in the shortest post-LGE T1 relaxation time tertile
had significantly higher gal-3 levels compared to the other two
tertiles (15.2 ± 5.9 ng/mL vs. 10.4 ± 3.7 ng/mL, p = 0.002
between tertiles 1 vs. 2 and 15.2 ± 5.9 vs. 10.4 ± 2.8, p = 0.002
between 1 vs. 3). However, there was no significant difference
in ST2 (22.4 ± 7.7 ng/mL vs. 20.1 ± 5.5 ng/mL, p = 0.81 and
22.4 ± 7.7 vs. 18.4 ± 6.4, p = 0.19), PIIINP (4.2 ± 1.5µg/L vs.
3.5 ±1.0µg/L, p = 0.14 and 4.2 ± 1.5µg/L vs. 3.7 ± 0.7µg/L,
p = 0.45), or PINP (34.7 ± 9.3 ng/mL vs. 38.4 ± 15.5 ng/mL,
p = 1.0 and 34.7 ± 9.3 ng/mL vs. 35.8 ± 22.6 ng/mL, p = 1.0)
between the LGE T1 tertiles (Figure 1).
Higher E/é-values in the shortest post-LGE relaxation time
tertile were also observed compared to the longest relaxation time
tertile (11.8 ± 5.7 vs. 7.7 ± 2.8, p = 0.009) (Figure 2). The
subjects in the highest E/é tertile had significantly higher serum
levels of gal-3 (10.9± 4.1 ng/mL vs. 15.4± 5.2 ng/mL, p = 0.002
between tertiles 1 vs. 3 and 9.8± 2.8 ng/mL vs. 15.4± 5.2 ng/mL,
p < 0.001 between tertiles 2 vs. 3), ST2 (18.6 ± 6.6 ng/mL vs.
24.2 ± 7.3 ng/mL, p =0.025 and 18.5 ± 5.4 ng/mL vs. 24.2 ±
7.3 ng/mL, p = 0.029), and PIIINP (3.4 ± 0.8µg/L vs. 4.5 ±
1.8µg/L, p = 0.001 and 3.6 ± 0.8µg/L vs. 4.5 ± 1.8µg/L,
p = 0.007) (Figure 3).
Discussion
Main Findings
Gal-3 was the only serum biomarker that had a significant
correlation to diffuse myocardial fibrosis estimated by LGE CMR
T1 mapping in patients with stable CAD. Elevated levels of
other biomarkers, such as ST2 and PIIINP, had no significant
association to fibrosis, but these biomarkers were associated
with impaired left ventricular filling assessed by tissue Doppler
echocardiography. Furthermore, LGE T1 relaxation time was
closely associated with E/é showing that diffuse myocardial
fibrosis is an important determinant of cardiac diastolic function
in patients with uncomplicated stable CAD. Myocardial fibrosis
TABLE 1 | Characteristics of patients divided according to the amount of fibrosis measured by magnetic resonance imaging.
1st 2nd 3rd p-value
Age (years) 68.7± 8 67.8± 8.8 64.6±7.0 0.27
BMI 28.1± 4.2 28.0± 4.9 27.8±3.2 0.97
SBP/DBP (mmHg) 155/82± 21/13 145/80± 27/10 147/82±21/9 0.29/0.75
EF (%) 66%± 7 63%± 5 65%±6 0.16
LV mass 236± 58 252± 77 211±30 0.13
LV mass index 123± 27 131± 35 112±15 0.12
S-creatinine (µmol/L) 87± 26 77± 18 73±16 0.47
S-Cholesterol 4.1± 1.1 3.8± 0.8 4.0±0.9 0.73
S-LDL-Cholesterol 2.4± 0.9 2.3± 0.7 2.2±0.9 0.83
B-HbA1c (%) 6.6± 1.0 6.4± 1.0 6.1±0.7 0.29
BNP (ng/L) 91± 76 73± 71 59±65 0.77
hs-CRP (mg/L) 3.7± 9.1 2.9± 5.4 1.7±2.1 0.55
Syntax score 2.9± 4.4 6.9± 11.2 3.7±5.7 0.29
Smoking (ongoing/ex) 10%/52% 14%/55% 5%/50% 0.86
Type II diabetes 76% 77% 75% 0.99
Sex (male) 57% 41% 50% 0.57
Medication
B-blocker 86% 86% 80% 0.83
ACEi/ARB 71% 68% 50% 0.31
CCB 24% 14% 5% 0.23
Diuretics 43% 18% 40% 0.17
Statins 91% 91% 90% 0.99
BMI, body mass index; BP, blood pressure; EF, ejection fraction; LV, left ventricle; LDL, low-density lipoprotein; HbA1c, Glycosylated Hemoglobin, Type A1C; BNP, brain natriuretic
peptide; hs-CRP, high sensitive C-reactive protein; ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor blocker; CCB, calcium channel blocker.
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FIGURE 1 | The correlations between LGE T1 relaxation time and
biomarkers. When subjects were divided into tertiles according to LGE T1
relaxation time (1st tertile had the shortest LGE T1 relaxation time and the
highest amount of interstitial fibrosis) Galectin-3 was the only biomarker of
fibrosis that was significantly higher in the 1st tertile compared to the other
two tertiles.
FIGURE 2 | The correlation between LGE T1 relaxation time and
diastolic function. When subjects were divided into tertiles according to LGE
T1 relaxation time (1st tertile had the shortest LGE T1 relaxation time and the
highest amount of interstitial fibrosis) the 1st tertile had significantly more
impaired LV diastolic function as measured by E/é-values compared to the 3rd
tertile.
had no significant relationship with any demographic variable,
left ventricular systolic function, severity of CAD (Syntax score),
or any metabolic risk variable.
Cardiac MRI
CMR has emerged as a non-invasive imaging method for
focal fibrosis but it also allows the assessment of diffuse
interstitial fibrosis. Isolated post-contrast T1 relaxation time has
been shown to have a strong correlation with histologically
confirmed myocardial fibrosis in small studies involving patients
with heart failure (Iles et al., 2008; Miller et al., 2013). T1
relaxation time has also some correlation with echocardiographic
markers of impaired diastolic function such as septal E’ and
E/é in patients with diabetes but no underlying CAD as
a marker of so-called diabetic cardiomyopathy (Jellis et al.,
2011; Ng et al., 2012). One study including patients with
ischemic cardiomyopathy also showed a correlation between
E/é and visually estimated LGE (Raman et al., 2009). Isolated
post-contrast T1 relaxation time was also the only variable
that correlated with invasively measured LV stiffness after
multivariate analysis in cardiac transplant recipients (Ellims et al.,
2014).
Previous studies using T1 relaxation time analysis to estimate
the amount of fibrosis have excluded patients with stable
uncomplicated CAD. In our study we were able to show
that also in patients with CAD, isolated post-contrast T1
relaxation time correlates with diastolic filling properties, even
when areas of visible LGE where excluded from analysis. In
post hoc analysis we could show that the patients in the
tertile with the highest amount of interstitial fibrosis in CMR
had significantly higher E/é-values than the tertile with least
fibrosis.
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FIGURE 3 | The correlation between diastolic function and biomarkers. When subjects were divided into tertiles according to LV diastolic function (E/é-values)
the tertile with the most impaired LV diastolic function had significantly higher serum levels of GAL-3, ST2, and PIIINP compared to the other two tertiles.
Biomarkers
Myocardial collagen tissue consists mostly of collagen type I and
III. Procollagen N-terminal peptides, which can be measured
from blood samples, have been used as surrogates of myocardial
fibrosis. Nevertheless there has been some controversial evidence
of PINP and PIIINP as biomarkers of collagen biosynthesis
and as predictors of outcome of heart failure patients. Gal-3
and ST2 are more novel biomarkers of fibrosis. Gal-3 is an
important mediator that induces fibroblasts to proliferate and
deposit collagen, which contributes to myocardial fibrosis and
remodeling. ST2 is a member of the interleukin receptor family
and the gene expression of ST2 is upregulated in fibroblasts
and cardiomyocytes subjected to mechanical stress. ST2 also
prevents the IL-33 effects in reducing fibrosis and hypertrophy.
GAL-3 (Lok et al., 2010, 2013; De Boer et al., 2011; Ho
et al., 2012; Lopez-Andrés et al., 2012) and ST2 (Pascual-
Figal et al., 2009; Manzano-Fernandez et al., 2011) have been
shown to have predictive value for adverse cardiac events and
mortality especially in patients with heart failure and ST2
also in patients after acute coronary syndrome (Eggers et al.,
2010).
In this study we found a correlation between the LGE
T1 relaxation time and GAL-3, but the other biomarkers of
fibrosis did not have a significant correlation to myocardial
fibrosis measured by LGE CMR. One of the reasons for these
observations might be that ST2 concentrations are thought to
raise as a result of increased myocardial strain whereas gal-3 can
be seen as an initiator of collagen deposition and therefore as a
better surrogate of incipient or existing interstitial fibrosis even
without systolic or diastolic impairment.
In the tertile analysis divided according to diastolic function
i.e., E/é-values, we were able to show significant differences
in the biomarker levels of Gal-3, ST2, and PIIINP between
the most marked diastolic impairment tertile compared to the
other two tertiles. These data provide evidence of the utility
of these serum biomarkers in the rapid diagnosis of cardiac
diastolic dysfunction, but these findings need confirmation in
larger patient samples.
Limitations
The relatively small sample size of the study prevents definite
conclusions regarding the lack of correlation between some of
the biomarkers, such ST2 and PIIINP, and myocardial fibrosis
measured by CMR. Measurement of relaxation time T1 by
the LGE method may also have some limitations in terms of
reliable quantification of diffuse myocardial fibrosis. Despite
these limitations, we feel that the present findings provide
some useful information about the value of serum biomarkers
as predictors of both myocardial fibrosis and cardiac diastolic
properties.
Conclusion
In patients with uncomplicated CAD, serum biomarkers,
especially gal-3, are associated with diffuse interstitial fibrosis
imaged with cardiac MRI. Additionally, these biomarkers
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are associated with echocardiographically measured impaired
LV diastolic filling properties. These results suggest that LV
interstitial fibrosis plays an important role in impaired diastolic
function among CAD patients and the level of cardiac diastolic
dysfunction can be assessed with serum biomarkers of fibrosis.
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